Time: 2024-11-29
A new discovery in treat serious asthma and chronic clogging pneumonic disease ( COPD ) attack has been acclaim by doctor as a potential gamechanger for patient. The test concentrate on a medicine name Benralizumab, a monoclonal_antibody antibody that target particular White blood cell to reduce lung inflammation. The consequence, print in the Lancet Respiratory Medicine diary, show that offer patient an injection of Benralizumab was more effective than the current treatment of steroid tablet, reduction the need for foster care by 30%.
lead research_worker Prof Mona Bafadhel from Kings College London state that this new approach could revolutionize the treatment of asthma and COPD, conditions that have not see any significant promotion in treatment for the past 50 old_age despite causing million of death worldwide annually. The test involve 158 people who necessitate checkup attention for their asthma or COPD attack, with those agony from eosinophilic aggravation being suitable for treatment with Benralizumab.
The survey compare the effectiveness of Benralizumab with steroid tablet in pull_off respiratory symptom such as cough, wheeze, and shortness_of_breath. After 28 days, patient on Benralizumab show better symptom compare to those on steroid. Additionally, after 90 days, there be significantly fewer treatment failure in the Benralizumab group, lead to fewer visit to healthcare supplier and a better quality of life for patients.
The research_worker foreground that steroid, the current standard treatment, semen with severe side effects such as an increase hazard of diabetes and osteoporosis. Therefore, the potential switch to Benralizumab could offer significant benefit to patient with asthma and COPD. AstraZeneca supply the drug for the survey and fund the research, emphasizing the importance of new promotion in treat these respiratory conditions.
Benralizumab has already show promise in pull_off severe asthma, but this test show its potential for treat acute_accent asthma attack, which could rich_person a major impact on better result for patient. Dr Samantha Walker, director of research and invention at Asthma and Lung UK, admit the significance of this new treatment option but also foreground the pressing need for More support in lung health research to address the lack of new treatment for asthma and COPD attack in the past one-half-century.
In decision, the survey on Benralizumab represent a significant measure forward in the treatment of asthma and COPD aggravation, offer hope for million of patient worldwide. The potential for this medicine to be administer safely and effectively during acute_accent attack could lead to better result and better quality of life for person life with these chronic respiratory conditions. foster research and test are plan to gather More evidence on the benefit of Benralizumab in treat acute_accent aggravation of asthma and COPD.